Clinical Trials in MDS and Acute Myeloid Leukaemia (AML)

 

Trial Title

 

Trial Description

 

More information (external website)

 

Li-1

 

This trial is looking at new drugs in combination with cytarabine (Ara C) for acute myeloid leukaemia (AML) and high risk myelodysplastic syndrome (MDS).

 

 

AML18

 

This trial is looking at treatment for acute myeloid leukaemia (AML) and high risk myelodysplastic syndrome (MDS). It is designed mainly for people over 60 years of age who are fit enough to have intensive chemotherapy. But some younger people may be able to take part.

 

 

AML19

 

This trial is looking at different treatments for acute myeloid leukaemia (AML) and high risk myelodysplastic syndrome (MDS). It is for people who are fit enough to have intensive treatment.

 

 

Camellia

 

This trial is looking at a new drug called Hu5F9-G4 to treat acute myeloid leukaemia (AML) and myelodysplastic Syndrome (MDS). It is open to people whose AML or MDS has not responded to treatment (refractory) or came back after treatment (relapsed)

 

 

ELASTIC

 

This trial is looking at a drug called eltrombopag alongside azacitidine for people with myelodysplastic syndrome (MDS)

 

 

MIRROS

 

This trial is for people whose acute myeloid leukaemia (AML) has come back or continued to grow following their first or second treatment.

 

 

IDHENTIFY

 

This study is for people aged 60 years or over with AML which has come back or remained after 2 or 3 prior treatments with the IDH2 mutation.

 

 

ASTELLAS

 

The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo after the transplant.

 

 

MEDI4736

 

This is a Phase 1 trial investigating the effect of durvalumab, with or without tremelimumab and/or azacitidine in patients with myelodysplastic syndrome, who have not responded or relapsed after treatment with azacitidine or decitabine.

 

;